European Commission approves Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Basel, 11 July 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has granted conditional marketing authorisation for…

Related Keywords

Switzerland ,Japan ,United States ,Australia ,Melbourne ,Victoria ,Canada ,America ,Loren Kalm ,Michael Dickinson ,Nathalie Altermatt ,Kirti Pandey ,Karsten Kleine ,Sileia Urech ,Levi Garraway ,Roche Group ,Peter Maccallum Cancer Centre ,European Commission ,Head Of Global Product Development ,Genentech ,Roche Group Media Relations ,European Medicines Agency Summary Of Product Characteristics ,Drug Administration ,World Health Organization ,Chief Medical Officer ,Global Product ,Associate Professor ,Royal Melbourne Hospital ,New England Journal ,Fixed Duration Columvi ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,European Medicines Agency Summary ,World Health ,Cancer Incidence ,Refractory Diffuse Largeb Cell ,